These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 4564341)

  • 21. [Biochemistry and treatment of Parkinson's disease].
    Barbeau A
    Laval Med; 1970 Sep; 41(7):902-5. PubMed ID: 5509487
    [No Abstract]   [Full Text] [Related]  

  • 22. Peripheral aromatic L-amino acids decarboxylase inhibitor in Parkinsonism. I. Effect on O-methylated metabolites of L-dopa-2- 14 C.
    Messiha FS; Hsu TH; Bianchine JR
    J Clin Invest; 1972 Feb; 51(2):452-5. PubMed ID: 5009125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [L-Dopa in parkinsonism, myth or reality].
    Henry P
    Bord Med; 1970 Feb; 3(2):393-7. PubMed ID: 5425873
    [No Abstract]   [Full Text] [Related]  

  • 24. Experimental evaluation of L-dopa penetration in brain.
    De la Torre JC; Mullan S
    Trans Am Neurol Assoc; 1971; 96():227-9. PubMed ID: 5159088
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of Parkinsonism with L-dopa].
    Diaz Pérez G; Asenjo A; Chiorino R; Donoso P
    Neurocirugia; 1970; 28(1):17-23. PubMed ID: 5473365
    [No Abstract]   [Full Text] [Related]  

  • 26. Biosynthesis and metabolism of the catecholamines.
    Sandler M
    Schweiz Med Wochenschr; 1970 Mar; 100(12):526-31. PubMed ID: 4906882
    [No Abstract]   [Full Text] [Related]  

  • 27. [Study of dopamine and noradrenaline in the brains of three patients with Parkinson's disease who died in the course of treatment with L-dopa].
    Buscaino GA; Sori A; Campanella G
    Rev Neurol (Paris); 1972 Aug; 127(2):301-2. PubMed ID: 4666634
    [No Abstract]   [Full Text] [Related]  

  • 28. [Disturbances of catecholamine metabolism (with special reference to dopamine) in the Parkinsonian syndrome].
    Tissot R
    Presse Med (1893); 1969 Apr; 77(17):617-8. PubMed ID: 5785080
    [No Abstract]   [Full Text] [Related]  

  • 29. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
    Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
    [No Abstract]   [Full Text] [Related]  

  • 30. L-Dopa and Parkinsonism.
    Calne DB; Sandler M
    Nature; 1970 Apr; 226(5240):21-4. PubMed ID: 4907560
    [No Abstract]   [Full Text] [Related]  

  • 31. Catecholamines and neurologic diseases.
    Wurtman RJ
    N Engl J Med; 1970 Jan; 282(1):45-6. PubMed ID: 5409471
    [No Abstract]   [Full Text] [Related]  

  • 32. [Catecholamine metabolism in different forms of Parkinson's disease].
    Selikhova MV; Kogan BM; Serkin GV; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):37-40. PubMed ID: 12378880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A hort-term evaluation of L-dopa therapy in 34 patients with parkinsonism.
    Mones RJ; Elizan TS
    J Mt Sinai Hosp N Y; 1969; 36(6):503-15. PubMed ID: 5261089
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of Parkinson's disease with L-dopa].
    Guglielmi L; Vecchi L
    Clin Ter; 1970 May; 53(3):259-69. PubMed ID: 4917328
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapeutic implications in Parkinsonism of m-tyramine formation from L-dopa in man.
    Sandler M; Goodwin BL; Ruthven CR
    Nature; 1971 Feb; 229(5284):414-5. PubMed ID: 4926994
    [No Abstract]   [Full Text] [Related]  

  • 36. Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).
    Yahr MD; Duvoisin RC; Mendoza MR; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1971; 96():55-8. PubMed ID: 5159129
    [No Abstract]   [Full Text] [Related]  

  • 37. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.
    Imai K; Sugiura M; Kubo H; Tamura Z; Oya K
    Chem Pharm Bull (Tokyo); 1972 Apr; 20(4):759-64. PubMed ID: 5045616
    [No Abstract]   [Full Text] [Related]  

  • 38. L-dopa in Parkinsonism. A possible mechanism of action.
    Ng LK; Chase TN; Colburn RW; Kopin IJ
    Neurology; 1972 Jul; 22(7):688-96. PubMed ID: 4673250
    [No Abstract]   [Full Text] [Related]  

  • 39. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease.
    Hare TA; Vanna S; Beasley B; Chambers R; Vogel WH
    J Lab Clin Med; 1971 Feb; 77(2):319-25. PubMed ID: 5540775
    [No Abstract]   [Full Text] [Related]  

  • 40. Appearance and concentrations of catecholamines and their biosynthesis in the embryonic and developing chick.
    Ignarro LJ; Shideman FE
    J Pharmacol Exp Ther; 1968 Jan; 159(1):38-48. PubMed ID: 5643949
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.